Corporate Profile

NovaBay is focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and community environments. Many of these infections have become increasingly difficult to treat because of the rapid increase in infectious microbes that have become resistant to current drugs. Our in vitro and in vivo tests have demonstrated that our compounds kill a wide range of bacteria, viruses and other infection causing microbes, including those that are resistant to multiple antibiotics. We are developing hospital indications ourselves and have partnered certain other indications with Alcon, the world's leading eye care company, and with Galderma S.A., a global leading pharmaceutical company dedicated exclusively to the field of dermatology.

Press Releases

May 18, 2009

NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results

Apr 22, 2009

NovaBay® Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide Compounds

Apr 7, 2009

NovaBay® Pharmaceuticals Appoints Professor John A. Soderquist, Ph.D. to its Scientific Advisory Board

Apr 1, 2009

NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results

Mar 25, 2009

NovaBay and Galderma Enter into Global Agreement to Develop and Commercialize NovaBay’s Novel Aganocide Drugs for Major Dermatological Conditions

Mar 23, 2009

NovaBay Pharmaceuticals’ Scientific Advisor Receives American Chemical Society’s Highest Award

Mar 7, 2009

NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection

Mar 4, 2009

NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting

Feb 23, 2009

NovaBay Pharmaceuticals, Inc. (NBY) Receives Broadcast And Print Media Coverage

Feb 4, 2009

NovaBay Pharmaceuticals CEO Dr. Ron Najafi To Present at the 11th Annual BIO CEO & Investor Conference

Jan 20, 2009

NovaBay (NBY) Appoints Harry F. Hixson, Jr., PhD, Former Amgen President/Chief Operating Officer To Its Board of Directors

Jan 13, 2009

NovaBay's NVC-422 Cleared by FDA for Human Clinical Trials in Ophthalmology

Jan 9, 2009

NovaBay Issued Key Composition of Matter Patent for Aganocide® Compounds

Jan 8, 2009

NovaBay announces Retirement of Senior Executive

December 31, 2008

NovaBay Pharmaceuticals (NBY) Plans to Consolidate its Stock Listing
on the American Stock Exchange (AMEX)

November 18, 2008

Patient Enrollment Begins in Exploratory Phase II Trial of Novabay's Lead Aganocide Compound, NVC-422, in Catherer-Associated Urinary Tract Infections

November 14, 2008

Novabay Pharmaceuticals (NBY) Reports Third Quarter 2008 Financial Results

November 07, 2008

Novabay Pharmaceuticals To Present at the 10th Annual Rodman & Renshaw Healthcare Conference

October 29, 2008

What the World Needs Now: Safe Non-Antibiotic Anti-Infectives

October 27, 2008

The Future of Anti-Microbials is Here

October 23, 2008

NovaBay Pharmaceuticals To Present At The 7th Annual BIO Investor Forum

October 7, 2008

NovaBay Pharmaceuticals To Present Data On Lead Anti-Infective Compound at First-Ever ICAAC/IDSA Joint Meeting

October 1, 2008

NovaBay Pharmaceuticals to Present at the Maxim Group Annual Growth Conference

August 14, 2008

NovaBay to Present at 4th Annual Summer Technology Conference

August 14, 2008

NovaBay Pharmaceuticals (NBY) Reports Second Quarter 2008 Financial Results

August 7, 2008

NovaBay Pharmaceuticals Featured on KGO-TV San Francisco

July 31, 2008

NovaBay Pharmaceutical’s (NBY) CEO, Dr. Ron Najafi, Joins Distinguished Leaders Selected For This Year’s PharmaVOICE 100 Most Influential Leaders

July 29, 2008

NovaBay Begins Media Education Initiative to Promote New Approaches to Treating “Super Bugs”

July 17, 2008

NovaBay Announces Advancements In Dermatology Program

June 16, 2008

NovaBay Pharmaceuticals To Present At The BIO International Convention

May 19, 2008

NovaBay Announces Positive  Results From Phase  IIA Study of AgaNase™ For Nasal Decolonization of Staph including MRSA

May 14, 2008

NovaBay Pharmaceuticals (NBY) Reports First Quarter 2008 Results

May 12, 2008

NovaBay's Lead Aganocide Compound, NVC-422, Well Tolerated in the Bladder in Phase I Trial

March 18, 2008

NovaBay Pharmaceuticals (NBY) Publishes on the Design of New Class of Antimicrobial Compounds It Named Aganocides®

March 11, 2008

NovaBay Pharmaceuticals (NBY) Reports Fourth Quarter and Year End 2007 Results –Provides Corporate Highlights

March 7, 2008

NovaBay Pharmaceuticals Commences Phase I Human Clinical Trial for the Prevention of Catheter Associated Urinary Tract Infections

March 4, 2008

NovaBay Pharmaceuticals, Inc. Announces Year End 2007 Earnings Conference Call

February 26, 2008

NovaBay Pharmaceuticals Presentation at the 20th Annual Roth Capital
OC Growth Stock Conference Featured on MSN Money

February 12, 2008

NovaBay Pharmaceuticals Receives Allowance of Patent Covering NeutroPhase™ Product

February 7, 2008

NovaBay Pharmaceuticals To Present At Two Upcoming Healthcare Conferences

February 5, 2008

NovaBay Informs Investors of Inaccuracies on Yahoo! Finance

January 28, 2008

NovaBay Pharmaceuticals Rang Opening Bell At The American Stock Exchange Friday, January 25, 2008

January 22, 2008

NovaBay Pharmaceutical’s Investigational New Drug Application (IND) for the Prevention of Catheter Associated Urinary Tract Infections Cleared by FDA

January 10, 2008

NovaBay Pharmaceuticals Appoints Thomas J. Paulson Chief Financial Officer

December 5, 2007

NovaBay Pharmaceuticals, Inc. to Present at the New York Society of
Security Analysts Biotech/Specialty Pharma Conference

November 26, 2007

Novabay Pharmaceuticals, Inc. Announces positive phase 1 study results with lead Aganocide compound

November 20, 2007
 NovaBay Pharmaceuticals, Inc. Retains The Investor Relations Group of New York
NovaBay Pharmaceuticals, Inc. Featured In November/December Issue of PharmaVOICE

November 15, 2007
 NovaBay Announces Third Quarter 2007 Financial Results

October 31, 2007
NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock

 

Novabay